Fecal Calprotectin for Small Bowel Crohn's Disease: Is It a Cutoff Issue?
Crohn’s disease
fecal calprotectin
inflammatory bowel disease
magnetic resonance enterography
small bowel capsule endoscopy
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
30
07
2022
revised:
03
09
2022
accepted:
05
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
(1) Background: Fecal calprotectin (FC) correlates well with colonic inflammatory activity of Crohn’s disease (CD); data about relation of FC and small bowel (SB) lesions are still contradictory. The main aim was to analyze the relationship between FC levels and SB inflammatory activity in patients with established or suspected Crohn’s disease, assessed by small bowel capsule endoscopy (SBCE) or magnetic resonance enterography (MRE). (2) Methods: Two cohorts of patients were included: 1. Prospective data were collected from patients with established or suspected CD who underwent SBCE and FC (Cohort A); 2. A retrospective cohort of patients who underwent MRE and FC determination (Cohort B). Different cutoffs for FC were tested in both cohorts. (3) Results: 83 patients were included and 66 were finally analyzed. A total of 69.6% had SB lesions seen by SBCE (n = 25) or MRE (n = 21). FC mean levels were 605.74 + 607.07 μg/g (IQ range: 99.00−878.75), being significantly higher in patients with SB lesions compared to patients without lesions (735.91 + 639.70 μg/g (IQ range: 107.75−1366.25) vs. 306.35 + 395.26 μg/g (IQ range: 78.25−411.0), p < 0.005). For cohort A, 25 out of 35 patients had SB lesions and a significant correlation between Lewis Score and FC levels was achieved (R2: 0.34; p = 0.04). FC sensitivity (S), specificity (E), positive predictive value (PPV), and negative predictive values (NPV) for predicting SB lesions were 80%, 50%, 80%, and 50%, respectively, for FC > 100 µg/g. For cohort B, inflammatory SB activity, measured by MaRIA score, was detected in 21 out of 31 patients (67.7%). Patients with positive findings in MRE had significantly higher values of FC than those with no lesions (944.9 + 672.1 µg/g vs. 221 + 212.2 µg/g, p < 0.05). S, E, PPV, and NPV of FC were 89%, 50%, 77.2%, and 71.4% for FC levels > 100 µg/g. The higher sensitivity and specificity of the FC levels for the detection of SB lesions with SBCE and MRE was obtained for an FC cutoff >265 μg/g and >430 μg/g, respectively. (4) Conclusions: FC has a good correlation with the presence of SB lesions, assessed by SBCE and MRE, in patients with established or suspected Crohn’s disease. However, the ideal cutoff is here proven to be higher than previously reported. Multicenter and large prospective studies are needed in order to establish definitive FC cutoff levels.
Identifiants
pubmed: 36140627
pii: diagnostics12092226
doi: 10.3390/diagnostics12092226
pmc: PMC9497577
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Inflamm Bowel Dis. 2008 Sep;14(9):1219-28
pubmed: 18484672
Am J Gastroenterol. 2015 Jun;110(6):802-19; quiz 820
pubmed: 25964225
Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1137-44
pubmed: 27415156
J Crohns Colitis. 2016 Jun;10(6):663-9
pubmed: 26783346
Endoscopy. 2015 Apr;47(4):352-76
pubmed: 25826168
Arch Med Sci. 2015 Apr 25;11(2):353-61
pubmed: 25995752
Endoscopy. 2018 Apr;50(4):423-446
pubmed: 29539652
Rev Esp Enferm Dig. 2021 Mar;113(3):193-201
pubmed: 33207888
Aliment Pharmacol Ther. 2008 Jan 15;27(2):146-54
pubmed: 17956598
J Pediatr Gastroenterol Nutr. 2021 Aug 1;73(2):242-246
pubmed: 33872293
J Crohns Colitis. 2019 Mar 26;13(3):273-284
pubmed: 30137278
Gastrointest Endosc. 2017 Dec;86(6):1070-1078
pubmed: 28947363
Gut. 2009 Aug;58(8):1113-20
pubmed: 19136510
Aliment Pharmacol Ther. 2016 Jan;43(1):61-72
pubmed: 26548868
Gastroenterology. 2015 Oct;149(5):1275-1285.e2
pubmed: 26166315
Gastroenterol Hepatol. 2018 Oct;41(8):514-529
pubmed: 30293556
World J Gastroenterol. 2014 Jan 14;20(2):363-75
pubmed: 24574706
Am J Gastroenterol. 2010 Jan;105(1):162-9
pubmed: 19755969
Gastroenterology. 2011 May;140(6):1785-94
pubmed: 21530745
Inflamm Bowel Dis. 2018 Mar 19;24(4):775-780
pubmed: 29506048
Gut Liver. 2021 Sep 15;15(5):732-741
pubmed: 33361549
J Clin Gastroenterol. 2005 May-Jun;39(5):381-4
pubmed: 15815205
Gastroenterol Res Pract. 2015;2015:490183
pubmed: 26170833
Inflamm Bowel Dis. 2015 Jul;21(7):1572-9
pubmed: 26052967
Scand J Gastroenterol. 2011 Jun;46(6):694-700
pubmed: 21456899
Clin Gastroenterol Hepatol. 2017 Jan;15(1):56-62
pubmed: 27565523
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15
pubmed: 24983982
J Crohns Colitis. 2019 Feb 1;13(2):144-164
pubmed: 30137275
Inflamm Bowel Dis. 2006 Jun;12(6):524-34
pubmed: 16775498
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2269-2276.e4
pubmed: 30772585
Am J Gastroenterol. 2015 Sep;110(9):1316-23
pubmed: 26215531
Clin Chem Lab Med. 2013 Apr;51(4):825-31
pubmed: 23001318
Inflamm Bowel Dis. 2008 Jan;14(1):40-6
pubmed: 18022866
Intest Res. 2019 Apr;17(2):160-170
pubmed: 30704158
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Inflamm Bowel Dis. 2011 Aug;17(8):1759-68
pubmed: 21744431
Gut. 2009 Jun;58(6):859-68
pubmed: 19136508
J Crohns Colitis. 2013 Aug;7(7):556-85
pubmed: 23583097
J Crohns Colitis. 2013 Dec;7(12):982-1018
pubmed: 24184171
Gastroenterol Hepatol. 2013 Jun-Jul;36(6):400-6
pubmed: 23434080
Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38-39:101602
pubmed: 31327404
Inflamm Bowel Dis. 2004 Sep;10(5):661-5
pubmed: 15472532
Inflamm Bowel Dis. 2014 Apr;20(4):742-56
pubmed: 24562174